✦ LIBER ✦

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

✍ Scribed by Gregorc, V; Santoro, A; Bennicelli, E; Punt, C J A; Citterio, G; Timmer-Bonte, J N H; Caligaris Cappio, F; Lambiase, A; Bordignon, C; van Herpen, C M L

Book ID: 110000101
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 216 KB
Volume: 101
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605162

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1228 Phase I study of NGR-hTNF, a vascul

1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours

✍ G. Citterio; F.G. De Braud; V. Gregorc; T.M. De Pas; C. Noberasco; S. Boselli; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

6617 Phase II study of NGR-hTNF, a selec

6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)

✍ Santoro, A.; Citterio, G.; Pressiani, T.; Gregorc, V.; Rimassa, L.; De Braud, F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

6066 Phase II study of two doses of NGR-

6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens

✍ Sobrero, A.F.; Pessino, A.; Andretta, V.; Bennicelli, E.; Fornarini, G.; Caprion 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB